1. Introduction {#sec1}
===============

First reported in 1908, endometrial stromal sarcoma (ESS) is a rare uterine tumor known for its slow growth \[[@B1]\]. Originally known as interstitial endometrioma, endolymphatic stromal myosis, or low-grade endometrial stromal sarcoma ESS is recognized by its infiltrating margins and low mitotic activity \[[@B2]--[@B4]\]. Endometrial stromal sarcomas represent 0.2% of all genital tract malignancies and were previously subdivided into low- or high-grade categories based upon their mitotic index. High-grade endometrial stromal sarcomas are now termed poorly differentiated or undifferentiated uterine sarcomas due to its aggressive clinical course \[[@B5]--[@B10]\].

Typically diagnosed postoperatively on hysterectomy specimens, ESS has an indolent course and recurrent disease can occur up to twenty years after diagnosis. Primary ESS is treated surgically with a total abdominal hysterectomy and bilateral salpingo-oophorectomy and routine lymphadenectomy has not been found to improve overall survival rates \[[@B1], [@B3], [@B7], [@B8]\]. Recurrent ESS is commonly treated with progestins like other endometrial cancers but there is no consensus regarding optimal management \[[@B5]\]. ESS is hormonally responsive and contains estrogen and progesterone receptors \[[@B5], [@B11]--[@B13]\]. Patients with retained ovaries after a hysterectomy or those who receive estrogen hormone replacement have high recurrence rates; therefore, single agent estrogen replacement therapy is not recommended \[[@B5]\]. Progestins however are commonly used in the adjuvant setting to treat ESS \[[@B5]\]. The mechanism of action of progestins is to bind progesterone receptors and cause downregulation of gene transcription leading to decreased endometrial gland and stromal proliferation \[[@B11], [@B14]\]. Diminished endometrial gland and stromal proliferation make progestins beneficial for use in the adjuvant setting and at the time of disease recurrence. In addition, gonadotropin releasing hormone (GnRH) agonists downregulate GnRH receptors in the anterior pituitary leading to a hypoestrogenic state. Here, we present the long-term followup of a patient with recurrent endometrial stromal sarcoma treated with a progestin and GnRH agonist with excellent results.

2. Case Report {#sec2}
==============

A 41-year-old woman gravida 2 para 1 with a body mass index of 25 presented with menorrhagia, pelvic pain, and dysmenorrhea. Her past medical history was unremarkable. Her past surgical history was pertinent for a bilateral tubal ligation in 1991. After examination by her general gynecologist, she was found to have an enlarged uterus. No additional preoperative testing was performed. In November 1996, she underwent a total abdominal hysterectomy with bilateral salpingo-oophorectomy. The frozen section diagnosis revealed a uterine stromal tumor with rare mitotic figures. The final pathology diagnosed an International Federation of Gynecology and Obstetrics (FIGO) stage IA endometrial stromal sarcoma extending to the outer one third of the myometrium \[[@B15]\]. The fallopian tubes, ovaries, and uterine serosa were negative for malignancy. The uterus weighed 647 grams and measured 12.9 × 12 × 7 cm. Her postoperative course was uneventful and she required no further therapy. She continued her followup care under the management of her general gynecologist and remained without evidence of disease for two months.

A surveillance computer tomography of the abdomen and pelvis performed in January 1997 showed three 4-5 mm nodular densities in the right lower lobe of the lung. The densities were too small to biopsy and no comparison films were available. The patient was asymptomatic and therefore was managed conservatively. The lung densities remained stable in size until August 1997 when one density was found to have increased to 15 × 14 mm. A lung biopsy of the largest lesion was suspicious, but not diagnostic for a malignancy. The enlarged lung density was thought to clinically represent recurrent disease and the patient was referred to a medical oncologist in her area who recommended cytotoxic chemotherapy. The patient declined chemotherapy and desired a second opinion.

After referral to our medical center in November 1997, she was started on a regimen of megestrol 40 mg twice daily with monthly intramuscular injections of leuprolide 7.5 mg. Complete resolution of her lung nodules occurred in response to this regimen by January 1998. She remained on megestrol and a 3.75 mg dose of leuprolide until the date of last followup in June 2006. Now over 10 years after her initial surgery, she remains without evidence of disease.

3. Discussion {#sec3}
=============

Due to the rarity of ESS, it is difficult to conduct prospective randomized clinical trials to determine the optimal treatment regimen. Treatment has been defined by the experience gained from retrospective case series and case reports. The patient in this case was treated with megestrol and leuprolide based on our clinical experience with this regimen. Our experience with this combination has influenced the use of progestins with GnRH agonists by graduates of our department \[[@B16]\].

Treatment of recurrent ESS is unclear. Chu and colleagues published findings showing that 75% of patients with stage I disease did not recur if treated with adjuvant megestrol compared to 29% of similarly staged patients who did not receive adjuvant megestrol \[[@B5]\]. Based on these findings, the authors recommend adjuvant megestrol 160 mg daily \[[@B5]\]. Several other studies have highlighted the use of GnRH agonists, progestins, and aromatase inhibitors alone or in combination with effective therapies in the treatment of ESS \[[@B17]\]. One case report published in 2004 showed good response with single agent GnRH analogue, triptorelin, in a patient with recurrent ESS \[[@B18]\]. Recurrent ESS has also been treated with radiation, surgical reexcision, chemotherapy, or a combination of these modalities, however, data supporting these treatments are limited \[[@B5], [@B11], [@B19]--[@B24]\]. Hormonal therapy has been studied the most in ESS. In one case series of 13 women with recurrent ESS who received hormonal management, 46% had an objective response \[[@B21]\]. The type of progestin varied in this study, but despite the type of progestin used (megestrol, medroxyprogesterone acetate, or hydroxyprogesterone acetate), all of the patients treated with hormonal management had favorable outcomes, leading us to believe that the type of progestin is not as important as the effect of progestins on this disease entity \[[@B21]\]. While several other studies have documented the effectiveness of other hormonal agents such as tamoxifen, letrozole, or amnioglutethimide for the treatment of recurrent ESS, progestins are inexpensive, have a favorable safety profile, and have been extensively studied in the treatment of uterine malignancies \[[@B17], [@B20], [@B24]--[@B26]\]. Although small and retrospective in nature, these studies illustrate the importance of the hypoestrogenic environment provided by progestins and GnRH agonists in the management of recurrent ESS.

In conclusion, ESS is a rare uterine malignancy with long disease-free intervals. ESS is rarely diagnosed preoperatively and many patients will develop disease recurrence. We have had success in the long-term management of one patient with recurrent ESS using megestrol and leuprolide and we recommend its use but multicenter prospective trials are needed to determine optimal therapy for this disease entity in the recurrent setting.
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